Research shows that patients with type II diabetes treated with the glucagon-like peptide-1 (GLP-1) receptor agonists have an increased risk for developing sight-related complications such as sight-threatening diabetic retinopathy and optic nerve disorders.

Two papers published this week in the journal JAMA Network Open show that although the risk is modest, there is a significant risk increase for eye-related adverse events for patients with diabetes prescribed these drugs.

“GLP-1 receptor agonist medications have transformed the treatment of type II diabetes and obesity, with associated reductions in cardiovascular and nephrological complications,” write Rong Xu, PhD, a researcher at Case Western Reserve University School of Medicine, and colleagues in one of the papers.

“Despite

See Full Page